Company intelligence / Profile preview

Occuity

Reading, England, United Kingdomoccuity.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

Occuity has completed clinical trials for its PM1 Pachymeter with results published showing performance comparable to current market options. The PM1 has been submitted for CE marking in Europe and FDA clearance in the US. Early data from their SD1 diabetes screening prototype shows promising outcomes. Other products are at various stages from prototype to pre-clinical testing.

Therapeutic areas: EndocrinologyOphthalmologyNeurology
Modalities: Device (Handheld optical diagnostic devices)Non-pharmacological therapy (screening/monitoring technology)
Industry: Physiological Monitoring

Partnerships

Built a network of distribution partners ahead of launchmanufacturing supported by Surface Technology International (STI)awarded Innovate UK grantrecipient of Berkshire Business Capital Grant Fund

Beyond the preview

Go deeper on Occuity.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Occuity.

Explore the full profile